Daymark Wealth Partners’s TG Therapeutics TGTX Stock Holding History

Daymark Wealth Partners’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.07M	Buy	55,834 +123	+0.2%	+$5.03K	0.07%	191
2026 Q1	$1.85M	Buy	55,711 +6,183	+12%	+$184K	0.06%	217
2025 Q4	$1.48M	Buy	49,528 +28	+0.1%	+$914	0.05%	230
2025 Q3	$1.79M	Buy	49,500 +4,000	+9%	+$132K	0.06%	205
2025 Q2	$1.64M	Hold	45,500	–	–	0.06%	200
2025 Q1	$1.79M	Buy	45,500 +4,000	+10%	+$135K	0.08%	181
2024 Q4	$1.25M	Buy	41,500 +689	+2%	+$19.8K	0.05%	204
2024 Q3	$955K	Buy	40,811 +17,311	+74%	+$378K	0.04%	253
2024 Q2	$418K	Hold	23,500	–	–	0.02%	347
2024 Q1	$357K	Buy	23,500 +10,000	+74%	+$159K	0.02%	314
2023 Q4	$231K	Hold	13,500	–	–	0.01%	363
2023 Q3	$113K	Buy	+13,500	New	+$188K	0.01%	370

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Daymark Wealth Partners's TGTX Position: Q2 2026 in Review

Daymark Wealth Partners increased its TG Therapeutics (TGTX) stake by 0.22% in Q2 2026, buying an estimated $5.03K and bringing the position to 55,834 shares worth $3.07M. The position accounts for 0.07% of the portfolio, ranked #191.

Daymark Wealth Partners first reported a position in TGTX in Q3 2023 and has held it in 12 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Daymark Wealth Partners held 55,834 shares of TG Therapeutics worth $3.07M as of Q2 2026.
Daymark Wealth Partners bought 123 TG Therapeutics shares in Q2 2026, an estimated $5.03K.
TG Therapeutics made up 0.07% of Daymark Wealth Partners's portfolio in Q2 2026, its #191 holding.
Daymark Wealth Partners first reported a position in TG Therapeutics in Q3 2023 and has held it in 12 quarters since.
427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Daymark Wealth Partners's 13F filing for Q2 2026, filed 31 Jul 2026.